Does plasma HDL-C concentration interact with whole-body cholesterol metabolism?

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 23, Issue 4, 2013, Pages 279-284

  Leanca C C ^a   Nunes, V S ^a   Nakandakare, E R ^a   de Faria, E C ^b   Quintao, E C R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Cholesterol metabolism; Cholesterol synthesis; Diabetes mellitus; HDL; Insulin resistance

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

ANIMAL; BIOSYNTHESIS; BLOOD; CHOLESTEROL INTAKE; DIABETES MELLITUS; DRUG EFFECT; DYSLIPIDEMIA; GENETICS; HUMAN; INSULIN RESISTANCE; INTESTINE ABSORPTION; KINETICS; LIPID METABOLISM; REVIEW;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; CHOLESTEROL; CHOLESTEROL, DIETARY; CHOLESTEROL, HDL; DIABETES MELLITUS; DYSLIPIDEMIAS; HUMANS; INSULIN RESISTANCE; INTESTINAL ABSORPTION; KINETICS; LIPID METABOLISM;

EID: 84875072896     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2012.12.003     Document Type: Review

References (48)

1. Briel M., Ferreira-Gonzalez I., You J.J., Karanicolas P.J., Akl E.A., Wu P., et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009, 338:b92.
2. Rea T.J., Brown C.M., Sing C.F. Complex adaptive system models and the genetic analysis of plasma HDL-cholesterol concentration. Perspect Biol Med 2006, 49:490-503.
3. Barter P., Kastelein J., Nunn A., Hobbs, Future Forum Editorial Board High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 2003, 168:195-211.
4. Rashid S., Watanabe T., Sakaue T., Lewis G.F. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem 2003, 36:421-429.
5. Kontush A., Chapman M.J. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006, 58:342-374.
6. Miettinen T.A., Tilvis R.S., Kesäniemi Y.A. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol 1990, 131:20-31.
7. Kempen H.J., Glatz J.F., Gevers Leuven J.A., van der Voort H.A., Katan M.B. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J Lipid Res 1988, 29:1149-1155.
8. Vanhanen H., Kesäniemi Y.A., Miettinen T.A. Pravastatin lowers serum cholesterol, cholesterol-precursor sterols, fecal steroids, and cholesterol absorption in man. Metabolism 1992, 41:588-595.
9. Simonen P., Gylling H., Howard A.N., Miettinen T.A. Introducing a new component of the metabolic syndrome: low cholesterol absorption. Am J Clin Nutr 2000, 72:82-88.
10. Santosa S., Varady K.A., AbuMweis S., Jones P.J. Physiological and therapeutic factors affecting cholesterol metabolism: does a reciprocal relationship between cholesterol absorption and synthesis really exist?. Life Sci 2007, 80:505-514.
11. Matthan N.R., Pencina M., LaRocque J.M., Jacques P.F., D'Agostino R.B., Schaefer E.J., et al. Alterations in cholesterol absorption/synthesis markers characterize Framingham offspring study participants with CHD. J Lipid Res 2009, 50:1927-1935.
12. Simonen P.P., Gylling H., Miettinen T.A. Body weight modulates cholesterol metabolism in non-insulin dependent type 2 diabetics. Obes Res 2002, 10:328-335.
13. Ooi E.M., Ng T.W., Chan D.C., Watts G.F. Plasma markers of cholesterol homeostasis in metabolic syndrome subjects with or without type-2 diabetes. Diabetes Res Clin Pract 2009, 85:310-316.
14. Gylling H., Miettinen T.A. Inheritance of cholesterol metabolism of probands with high or low cholesterol absorption. J Lipid Res 2002, 43:1472-1476.
15. Miettinen T.A., Kesäniemi Y.A. Cholesterol absorption: regulation of cholesterol synthesis and elimination and within-population variations of serum cholesterol levels. Am J Clin Nutr 1989, 49:629-635.
16. Miettinen T.A., Gylling H., Strandberg T., Sarna S. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S investigators. BMJ 1998, 316:1127-1130.
17. Nunes V.S., Leança C.C., Panzoldo N.B., Parra E., Cazita P.M., Nakandakare E.R., et al. HDL-C concentration is related to markers of absorption and of cholesterol synthesis: study in subjects with low vs. high HDL-C. Clin Chim Acta 2011, 412:176-180.
18. Weingärtner O., Weingärtner N., Scheller B., Lütjohann D., Gräber S., Schäfers H.J., et al. Alterations in cholesterol homeostasis are associated with coronary heart disease in patients with aortic stenosis. Coron Artery Dis 2009, 20:376-382.
19. Weingärtner O., Lütjohann D., Böhm M., Laufs U. Relationship between cholesterol synthesis and intestinal absorption is associated with cardiovascular risk. Atherosclerosis 2010, 210:362-365.
20. Sehayek E., Ono J.G., Shefer S., Nguyen L.B., Wang N. Biliary cholesterol excretion: a novel mechanism that regulates dietary cholesterol absorption. Proc Natl Acad Sci U S A 1998, 95:10194-10199.
21. Harchaoui K.E., Franssen R., Hovingh G.K., Bisoendial R.J., Stellaard F. Reduced fecal sterol excretion in subjects with familial hypoalphalipoproteinemia. Atherosclerosis 2009, 207:614-616.
22. Beher W.T., Gabbard A., Norum R.A., Stradnieks S. Effect of blood high density lipoprotein cholesterol concentration on fecal steroid excretion in humans. Life Sci 1983, 32:2933-2937.
23. Paramsothy P., Knopp R.H., Kahn S.E., Retzlaff B.M., Fish B. Plasma sterol evidence for decreased absorption and increased synthesis of cholesterol in insulin resistance and obesity. Am J Clin Nutr 2011, 94:1182-1188.
24. Eriksson M., Carlson L.A., Miettinen T.A., Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation 1999, 100:594-598.
25. Nanjee M.N., Cooke C.J., Garvin R., Semeria F., Lewis G. Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res 2001, 42:1586-1593.
26. Niesor E.J., Chaput E., Staempfli A., Blum D., Derks M., Kallend Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects. Atherosclerosis 2011, 219:761-767.
27. Brousseau M.E., Diffenderfer M.R., Millar J.S., Nartsupha C., Asztalos B.F. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 2005, 25:1057-1064.
28. Castro-Perez J., Briand F., Gagen K., Wang S.P., Chen Y., McLaren D.G., et al. Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters. J Lipid Res 2011, 52:1965-1973.
29. Simmonds W.J., Hofmann A.F., Theodor E. Absorption of cholesterol from a micellar solution: intestinal perfusion studies in man. J Clin Invest 1967, 46:874-890.
30. Pertsemlidis D., Kirchman E.H., Ahrens E.H. Regulation of cholesterol metabolism in the dog. II. Effects of complete bile diversion and of cholesterol feeding on absorption, synthesis, accumulation, and excretion rates measured during life. J Clin Invest 1973, 52:2353-2367.
31. van der Velde A.E., Vrins C.L., van den Oever K., Kunne C., Oude Elferink R.P., Kuipers F., et al. Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol excretion in mice. Gastroenterology 2007, 133:967-975.
32. van der Veen J.N., van Dijk T.H., Vrins C.L., van Meer H., Havinga R., Bijsterveld K., et al. Activation of the liver X receptor stimulatestrans-intestinal excretion of plasma cholesterol. J Biol Chem 2009, 284:19211-19219.
33. Oliveira H.C., Nilausen K., Meinertz H., Quintão E.C. Cholesteryl esters in lymph chylomicrons: contribution from high density lipoprotein transferred from plasma into intestinal lymph. J Lipid Res 1993, 34:1729-1736.
34. Sipahi A.M., Oliveira H.C., Vasconcelos K.S., Castilho L.N., Bettarello A., Quintão E.C. Contribution of plasma protein and lipoproteins to intestinal lymph: comparison of long-chain with medium-chain triglyceride duodenal infusion. Lymphology 1989, 22:13-19.
35. Danielsen E.M., Hansen G.H., Rasmussen K., Niels-Christiansen L.L., Frenzel F. Apolipoprotein A-1 (apoA-1) deposition in, and release from, the enterocyte brush border: a possible role in transintestinal cholesterol efflux (TICE)?. Biochim Biophys Acta 2012, 1818:530-536.
36. Vrins C.L., Ottenhoff R., van den Oever K., de Waart D.R., Kruyt J.K., Zhao Y., et al. Trans-intestinal cholesterol efflux is not mediated through high density lipoprotein. J Lipid Res 2012, 53:2017-2023.
37. Brunham L.R., Kruit J.K., Iqbal J., Fievet C., Timmins J.M., Pape T.D., et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest 2006, 116:1052-1062.
38. Weidner C., Krempf M., Bard J.M., Cazaubiel M., Bell D. Cholesterol lowering effect of a soy drink enriched with plant sterols in a French population with moderate hypercholesterolemia. Lipids Health Dis 2008, 6:3151-3158.
39. Nakou E.S., Filippatos T.D., Kiortsis D.N., Derdemezis C.S., Tselepis A.D. The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opin Pharmacother 2008, 9:3151-3158.
40. Cohen J.C., Pertsemlidis A., Fahmi S., Esmail S., Vega G.L. Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc Natl Acad Sci USA 2006, 103:1810-1815.
41. Gylling H., Hallikainen M., Pihlajamäki J., Agren J., Laakso M. Polymorphisms in the ABCG5 and ABCG8 genes associate with cholesterol absorption and insulin sensitivity. J Lipid Res 2004, 45:1660-1665.
42. Gylling H., Hallikainen M., Kolehmainen M., Toppinen L., Pihlajamäki J., Mykkänen H., et al. Cholesterol synthesis prevails over absorption in metabolic syndrome. Transl Res 2007, 149:310-316.
43. Gylling H., Hallikainen M., Pihlajamäki J., Simonen P., Kuusisto J., Laakso M., et al. Insulin sensitivity regulates cholesterol metabolism to a greater extent than obesity: lessons from the METSIM Study. J Lipid Res 2010, 51:2422-2427.
44. Stranberg T.E., Salomaa V., Vanhanen H., Miettinen T.A. Associations of fasting blood glucose with cholesterol absorption and synthesis in nondiabetic middle-aged men. Diabetes 1996, 45:755-761.
45. Pihlajamäki J., Gylling H., Miettinen T.A., Laakso M. Insulin resistance is associated with increased cholesterol synthesis and decreased cholesterol absorption in normoglycemic men. J Lipid Res 2004, 45:507-512.
46. Leichtle A.B., Helmschrodt C., Ceglarek U., Shai I., Henkin Y., Schwarzfuchs D., et al. Effects of a 2-y dietary weight-loss intervention on cholesterol metabolism in moderately obese men. Am J Clin Nutr 2011, 94:1189-1195.
47. Briones E.R., Steiger D.L., Palumbo P.J., O'Fallon W.M., Langworthy A.L., Zimmerman B.R., et al. Sterol excretion and cholesterol absorption in diabetics and nondiabetics with and without hyperlipidemia. Am J Clin Nutr 1986, 44:353-361.
48. Drew B.G., Rye K.A., Duffy S.J., Barter P., Kingwell B.A. The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol 2012, 8:237-245.